A case of drug-induced Graves' Orbitopathy after combination therapy with Tremelimumab and Durvalumab.

Sabini, E; Sframeli, A; Marinò, M

Sabini, E; Sframeli, A; Marinò, M.

Affiliation

Sabini E; Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa, University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
Sframeli A; Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Marinò M; Department of Surgical, Medical and Molecular Pathology, Ophthalmology Unit I, University of Pisa, University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

J Endocrinol Invest ; 41(7): 877-878, 2018 07.

Article in En | MEDLINE | ID: mdl-29804271

Subject(s)

Adenocarcinoma/drug therapy; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Graves Ophthalmopathy/chemically induced; Lung Neoplasms/drug therapy; Adenocarcinoma/pathology; Aged; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms/pathology; Male; Prognosis

Key words

Durvalumab; Graves' orbitopathy; Tremelimumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols / Graves Ophthalmopathy / Lung Neoplasms Type of study: Prognostic_studies Limits: Aged / Humans / Male Language: En Journal: J Endocrinol Invest Year: 2018 Document type: Article

Fulltext

XML

PubMed Links

Search on Google